The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001176358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
25/08/2026
Date registered
Help: Date registered
22/09/2026
Date last updated
Help: Date last updated
22/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
22/09/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Change in whole body protein turnover over time in critically ill patients.
Scientific title
A prospective, single-centre, sequential physiological study to quantify changes in whole-body protein metabolism synthesis, breakdown, oxidation, and net balance) following exogenous enteral protein administration in critically ill patients over time.
Additional trial identifiers [1] 318237 0
Nil
Universal Trial Number (UTN)
Trial acronym
Metabolic Switch
Related trial records

Health condition
Health condition(s) studied:
Critical Illness 343290 0
Intensive Care Nutrition 343291 0
Muscle wasting 343476 0
Condition category
Condition code
Diet and Nutrition 339405 339405 0 0
Other diet and nutrition disorders
Musculoskeletal 339575 339575 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Observational
Patient registry
False
Target follow-up duration
Target follow-up type
Description of the intervention or exposure
A prospective, sequential physiological study in critically ill adults conducted every 7 days to a maximum of 3 time-points, censored at hospital discharge.
Study day 1: During mechanical ventilation early in the intensive care admission (within 7 days of ICU admission).
Study day 2 and 3: Will occur either in ICU, or on the post-ICU acute hospital ward.

Patients will undergo a 4 hour fast prior to study commencement. The plasma phenylalanine and tyrosine intracellular pools will be primed with a single intravenous bolus of labelled amino acids L-[ring-2H5] phenylalanine (2.0 µmol·kg-1) and L-[ring-3,5-2H2]-tyrosine (0.6 µmol·kg-1) (Cambridge Isotope Laboratory, Massachusetts, USA), followed by a continuous intravenous infusion of these same two tracers over 420 minutes (7 hours) to obtain an isotopic steady state (from t=-120 mins to t=300 mins).

At t=0 minutes, a gastric infusion of 24.4 g of Complete Amino Acid Mix (Nutricia, 20g protein, 340 kJ, 22.7 kJ/min) dissolved in water to 200ml with 30ml flavoured Cottees Lemon Crush cordial (218kJ, 12.8g carbohydrate) will be delivered over 15 minutes (from t=0 to t=15 mins). The amino acid mix will be administered by their current feeding route, either enterally into the nasogastric tube via syringe bolus or taken orally. The amino acid mix will be enriched with 5% of L-[ring-2H5]-phenylalanine to match plasma amino acid enrichment to prevent dilution of the labelled amino acid pool and 10% L-[1-13C]-phenylalanine to account for splanchnic extraction.

14 blood samples will be collected at pre-determined time points.

All study procedures (including administration of the amino acid tracer and amino acid mixture) are the same on all three study days. The amino acid tracers and amino acid mix is administered solely for the purposes of this research study and is not part of routine clinical care. The amino acid tracers are administered solely as part of the study methodology to enable measurement of changes in whole-body protein synthesis over the course of a hospital admission and not as a treatment or intervention.
Intervention code [1] 335127 0
Early Detection / Screening
Description of the comparator or control
Nil comparator or control group. Whole-body protein metabolism will be measured every 7 days during the hospital stay following ICU admission, for a maximum of three study days, to identify when patients transition from a catabolic to an anabolic state.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 346614 0
Change in post-prandial whole-body protein synthesis rate will be calculated from amino acid appearance and disappearance in the circulation, determined from plasma samples collected at specified time points across each study day
Timepoint [1] 346614 0
Pre-prandial (at -150, -60, -45, -30, -15, 0 minutes) and post-prandial (at 15, 30, 45, 60, 120, 180, 240, 300 minutes), on study days 1, 2 and 3.
Secondary outcome [1] 466740 0
Change in post-prandial whole-body protein breakdown rates will be calculated from amino acid appearance and disappearance in the circulation, determined from plasma samples collected at specified time points across each study day
Timepoint [1] 466740 0
Pre-prandial (at -150, -60, -45, -30, -15, 0 minutes) and post-prandial (at 15, 30, 45, 60, 120, 180, 240, 300 minutes), on study days 1, 2 and 3.
Secondary outcome [2] 466741 0
Change in post-prandial whole-body protein oxidation rates will be calculated from the rates of amino acid appearance and disappearance in the circulation, determined from plasma samples collected at specified time points across each study day
Timepoint [2] 466741 0
Pre-prandial (at -150, -60, -45, -30, -15, 0 minutes) and post-prandial (at 15, 30, 45, 60, 120, 180, 240, 300 minutes), on study days 1, 2 and 3.
Secondary outcome [3] 466742 0
Change in post-prandial whole-body net protein balance will be calculated from the rates of amino acid appearance and disappearance in the circulation, determined from plasma samples collected at specified time points across each study day
Timepoint [3] 466742 0
Pre-prandial (at -150, -60, -45, -30, -15, 0 minutes) and post-prandial (at 15, 30, 45, 60, 120, 180, 240, 300 minutes), on study days 1, 2 and 3.
Secondary outcome [4] 466759 0
Composite outcome of metabolite clusters and metabolic pathways that can predict the anabolic response of protein synthesis to enteral protein feeding
Timepoint [4] 466759 0
Pre-prandial (at -150, -60, -45, -30, -15, 0 minutes) and post-prandial (at 15, 30, 45, 60, 120, 180, 240, 300 minutes), on study days 1, 2 and 3.
Secondary outcome [5] 467380 0
Composite outcome of biomarkers associated with changes in whole-body protein synthesis in response to enteral protein feeding
Timepoint [5] 467380 0
Pre-prandial (at -150, -60, -45, -30, -15, 0 minutes) and post-prandial (at 15, 30, 45, 60, 120, 180, 240, 300 minutes), on study days 1, 2 and 3.
Secondary outcome [6] 467381 0
Composite outcome of clinical markers associated with the anabolic response of whole-body protein synthesis to enteral protein feeding
Timepoint [6] 467381 0
Study days 1, 2 and 3.

Eligibility
Key inclusion criteria
- Adults (18 years of age and above)
- Mechanically ventilated and expected to remain ventilated until the completion of study day 1
- Within 7 days of their index (first) ICU admission
- Suitable for nasogastric enteral feeding on study day 1
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
- Unlikely to survive until hospital discharge
- Unable to obtain informed consent from patient or person responsible/patient's next of kin believe the patient will not be willing to have study measurements completed following extubation
- Pregnancy
- Receiving dialysis
- Significant gastrointestinal disease (i.e. Crohn's Disease, Ulcerative Colitis) or gastrointestinal surgery to the oesophagus, stomach or small intestine
- Vegan
- Inborn errors of metabolism (e.g. Phenylketonuria, Galactosemia)
- Treating medical team deems study participation is not appropriate

Study design
Purpose
Screening
Duration
Longitudinal
Selection
Defined population
Timing
Prospective
Statistical methods / analysis
Based on previous work at a single timepoint, a sample size of 20 patients measured on at least two timepoints is expected to estimate the change in whole-body protein synthesis rates within a margin of error of 13.8 µmol/kg/h.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 30056 0
The Royal Adelaide Hospital - Adelaide
Recruitment postcode(s) [1] 46450 0
5000 - Adelaide

Funding & Sponsors
Funding source category [1] 322793 0
Government body
Name [1] 322793 0
Department of Health, Disability and Ageing - Medical Research Future Fund - Applied Research in Health
Country [1] 322793 0
Australia
Primary sponsor type
Government body
Name
Central Adelaide Local Health Network
Address
Country
Australia
Secondary sponsor category [1] 325719 0
None
Name [1] 325719 0
Address [1] 325719 0
Country [1] 325719 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321231 0
Central Adelaide Local Health Network HREC
Ethics committee address [1] 321231 0
Ethics committee country [1] 321231 0
Australia
Date submitted for ethics approval [1] 321231 0
29/08/2025
Approval date [1] 321231 0
22/10/2025
Ethics approval number [1] 321231 0
2025/HRE00337

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 153090 0
Ms Imogen Asser
Address 153090 0
Intensive Care Unit Research, 4G751, Royal Adelaide Hospital, Port Road, ADELAIDE SA 5000
Country 153090 0
Australia
Phone 153090 0
+610870741759
Fax 153090 0
Email 153090 0
Contact person for public queries
Name 153091 0
Lee-anne Chapple
Address 153091 0
Intensive Care Unit Research, 4G751, Royal Adelaide Hospital, Port Road, ADELAIDE SA 5000
Country 153091 0
Australia
Phone 153091 0
+610870741763
Fax 153091 0
Email 153091 0
Contact person for scientific queries
Name 153092 0
Lee-anne Chapple
Address 153092 0
Intensive Care Unit Research, 4G751, Royal Adelaide Hospital, Port Road, ADELAIDE SA 5000
Country 153092 0
Australia
Phone 153092 0
+610870741763
Fax 153092 0
Email 153092 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: No individual participant data will be available due to patient confidentiality.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.